Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Growing interest in repurposing metformin, a diabetes medication, for cancer treatment over the last 15 years.
• Significant research efforts, including large randomized clinical trials, have explored metformin's efficacy across various tumor types.

Purpose of the Study:

• To summarize the historical development of interest in metformin's oncological potential.
• To review the clinical program investigating metformin in cancer.
• To discuss lessons learned and the future of metformin in cancer research.

Main Methods:

• Review of existing literature and clinical trial data on metformin in cancer.
• Summary of studies investigating the intra-tumoral pharmacodynamic effects of metformin.
• Perspective analysis of past and future clinical investigations.

Main Results:

• Despite considerable interest and investment, clinical trial results for metformin as a cancer treatment have been largely disappointing to date.
• Studies have established the intra-tumoral pharmacodynamic effects of metformin in clinical settings.
• The overall efficacy of metformin in cancer treatment remains uncertain based on current evidence.

Conclusions:

• The clinical efficacy of metformin as a broad cancer therapeutic has not been conclusively demonstrated.
• Lessons learned from past trials are crucial for designing future investigations.
• The potential for further clinical investigation of metformin in specific cancer contexts warrants careful consideration.